Schering-Plough Agreement

RNS Number:2271S
Henderson Morley PLC
14 April 2008

                                                                   14 April 2008



                              HENDERSON MORLEY PLC
                                    (AIM)

                        Business: Drug Discovery Company

     HENDERSON MORLEY SIGNS SPONSORED DEVELOPMENT AND OPTION AGREEMENT WITH
                                SCHERING-PLOUGH


The Board of Henderson Morley plc, the AIM listed drug discovery company,
announces that it has signed a sponsored development and option agreement with
Schering-Plough Limited ("Schering") regarding the Grant of a Licence Agreement
for the intellectual property of its Koi Carp herpes vaccine.


HIGHLIGHTS

  * Option granted for Schering to take an exclusive worldwide licence to
    commercially exploit vaccine candidates produced by Henderson Morley;

  * Schering will pay undisclosed payments towards the development of the
    vaccine over a 15 month period;

  * If the Licence is granted it will be for an minimum term of 10 years;

  * Royalty payments will be based on Net Sales Revenue received by Schering;
    and

  * The Licence will include the right for Schering to sub-licence to third
    parties.


The sponsored development and option agreement is a precursor to the Grant of a
Licence Agreement for the intellectual property rights of Henderson Morley's Koi
Carp herpes vaccine. The Licence will be worldwide and Schering has agreed to
pay towards the development costs of the vaccine while the option agreement is
in place.

Schering-Plough Limited trades as Schering-Plough Animal Health. It is a
subsidiary of NYSE listed Schering-Plough, which is a global science-based
health care company with leading prescription, consumer and animal health
products.

Executive Chairman Andrew Knight said: "We are delighted to have signed this
agreement with Schering. This will help us to further develop our vaccine and we
look forward to working closely with a leader in the animal health arena."


                                   ---ENDS---



Enquiries:

HENDERSON MORLEY PLC                               Tel: 0121 442 4600
Andrew Knight, Chairman


BISHOPSGATE COMMUNICATIONS LTD                     Tel: 020 7562 3350
Maxine Barnes
Nick Rome


BREWIN DOLPHIN INVESTMENT BANKING                  Tel: 0113 241 0126
Neil Baldwin


HYBRIDAN LLP                                       Tel: 0203 159 5085
Stephen Austin/Claire Noyce


Further information on Henderson Morley plc can be accessed through the
Company's website at www.henderson-morley.com




Notes for editors

Henderson Morley

Henderson Morley was founded in 1996 with the objective of developing its anti-
viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform
and has been developed in-house and Henderson Morley wholly owns the patent IPR.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRVFLFFVZBEBBV

Henderson Mrly. (LSE:HML)
過去株価チャート
から 9 2024 まで 10 2024